5Jing You Lin Zhuang Bao Zhang Tang Wei Bo Yang Su Ying Ding Wu Li Rong Xue Wu Hong Li Zhang Yan Mei Zhang Shao Ming Yan Lu Zhang ~1Department of Infectious Diseases,The First Affiliated Hospital of Kunming Medical College,Kunming 650032,Yunnan Province,China ~2Departrnent of Hepatology,Kunming Third Municipal People’s Hospital,Kunming 650041,Yunnan Province,China.A randomized controlled clinical trial on the treatment of Thymosin-a1 versus interferon-α in patients with hepatitis B[J].World Journal of Gastroenterology,2001,7(3):411-414. 被引量：48
2[2]Sin JI, Kim JJ, Arnold RL, et al. IL-12 gene as a DNA vaccine adjuvant in a herpes mouse model: IL-12 enhances Th1 - type CD4 +T cell - mediated protective immunity against herpes simplex virus -2 challenge. J Immunol, 1999,162(5) :2912 ～ 2921
3[3]Nunberg JH, Doyle MV, York SM, et al. Interleukin 2 acts as an ad -juvant to increase the potency of inactivated rabies virus vaccine.Proc Natl Acad Sci USA, 1989,86(11) :4240 ～ 4243
4[4]Chow YH, Huang WL, Chi WK, et al. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin - 2. J Virol, 1997,71( 1 ): 169 ～ 178
5[5]Geissler M, Gesien A, Wands JR. Inhibitory effects of chronic ethanol consumption on cellular immune responses to hepatitis C virus core protein are reversed by genetic immunizations augmented with cytokine - expressing plasmids. J Immunol. 1997, 159(10):5107 ～ 5113
6LONG Z,SUN C S,WHITE E M,et al.Hepatitis B viral clearance studies using duck virus model [J].Dev Biol Stand,1993,81:163-168.
7RASI G,PIERIMARCHI P,SINIBALDI VALLEBONA P,et al.Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma [J].Int Immunopharmacol,2003,3(8):1169-1176.
8DELANEY W 4th,BARTHOLOMEUSZ A,LOCAMINI S A.Evolving therapies for the treatment of chronic hepatitis B virus infection [J].Expert Opin Investig Drugs,2002,11(2):169-187.
9SUGAHARA S,ICHIDA T,YAMAGIWA S,et al.Thymosin-a1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B [J].Hepatology Research,2002,24:346-354.
10AMARAPURKAR D,DAS H S.Thymosin alpha in the treatment of chronic hepatitis B:an uncontrolled open-label trial [J].Indian J Gastroenterol,2002,21(2):59-61.
5Cantagrel A, Navaux F, Nourhashemi F, et al. Interleukin-1 receptor antagonist,interleukin-4 and interleukin-10 gene polymorphisms [J]. Arthritis & Rheumatism,1999,42(6):1 093 -1100.
6Pociot F,Molvig J,Wogensen L,et al. A Taql polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro [J]. Eur J Clin Invest, 1992,22 : 396 - 402.
7Nie Q. The progression of treatment in serious hepatitis [ J ]. Chin J Gastro Hepa, 2005, 118( 6): 401 -414.
8Wai CT , Fontana RJ , Poison J , et al. Clinical outcome and virologi- cal characteristics of hepatitis B-related acute liver failure in the Unit- ed States[J]. J Viral Hepat, 2005, 12(2) : 192 -1981.
9Nanji AA, Jokelainen K, Fotouhinia M, et al. Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotox- in, and chemokines [ J ]. Am J Physiol Gastroi ntest Liver Physiol, 2001, 281(6) : G1348 -1356.
10Galley PE, Barton YW, Kinser S, et al. Involvement of cyclooxygen- ase-2 in the potentiation of allyl alcohol-induced liver injury by bacteri- al lipopolysaccharide[ J]. Toxicol Appl Pharmacol, 2001, 174 (2) : 113 -121.
